Swoop Launches Predictive AI Adherence Targeting
First-of-its-kind targeting predicts which patients will become non-adherent in the next 30 days
New offering...
First-of-its-kind targeting predicts which patients will become non-adherent in the next 30 days
New offering...
Kurt Robinson, SVP of Business Development for Swoop sat down with Jeanette Geer, Sr. Director of Healthcare Strategy...
By: Emilie Branch, Content Manager, Swoop
In healthcare marketing, the most successful campaigns begin with a deep...
By: Erin Ruggiero, Chief Digital Officer, Swoop
Introduction
Pharmaceutical companies want to drive disease awareness,...
By: Scott Rines, President, Swoop
Pharmaceutical companies want to drive disease awareness, guide...
By: Scott Rines, President, Swoop
Pharmaceutical companies want to drive disease awareness, guide...
The mission of the pharmaceutical industry is straightforward: Educate patients about disease states and the therapies that could effectively treat their conditions, as well as enable them to become active participants in their medical journey. But while the "what” pharmaceutical companies can say and the “how” they must say it is well regulated by the FDA, the privacy challenge comes from the “who” you can educate and how you choose to target them. These very real privacy issues are compounded by an increasingly complex set of federal and state laws, as well as self-regulatory guidelines. Privacy issues are probably unavoidable. But are you prepared? Our CEO Ron Elwell moderated a panel discussion on how you can meet the privacy challenges of today and the future by developing a deeper awareness of your company, your patient and your advertising supply chain.
Cross-channel DTC advertising has traditionally been deployed by the pharmaceutical industry. However, with the consumerization of healthcare initiated by the digitally-savvy, always-on patient, the adoption of this medium by medical device manufacturers is now at the forefront of patient engagement and activation strategies. Abbott, Real Chemistry and Swoop discuss how Abbott opened direct dialogue with over 6.5 million consumers about a cardiovascular disease with which most are not familiar, educated them about an innovative device that could effectively remedy their condition, as well as enabled them to become active participants in their diagnostic and treatment journey to create better outcomes.